Study of rozanolixizumab for ocular myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests an investigational medication called rozanolixizumab for people who have ocular myasthenia gravis (MG), where weakness is only in the eye muscles. The medicine is given as an injection under the skin and may help improve symptoms like drooping eyelids or double vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a diagnosis of ocular myasthenia gravis (weakness only in your eye muscles)
- Your diagnosis is confirmed either by specific antibodies (AChR or MuSK) or by other nerve and muscle tests
- Your eye symptoms started less than 3 years ago, or if longer ago, they improved with treatment in the past year
- You meet a certain level of symptom severity (a score of 6 or more on a patient-reported eye symptom questionnaire)
- You are either on a stable treatment dose for at least 30 days or not on any treatment for your eye symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues treatment with rozanolixizumab for people who have already received at least one dose in a previous trial (MG0038). It looks at how safe and effective the drug is over a longer period.
This trial tests whether a combination of steroid medicine (corticosteroid) and a targeted immune drug (rituximab) can prevent mild eye-muscle weakness from spreading to other muscles. It is for people newly diagnosed with ocular myasthenia who have not yet taken immune-suppressing treatments.
This real-world study looks at how different immunosuppressant medicines work for people with non-thymoma ocular myasthenia gravis (eye symptoms due to MG). It may help doctors understand which treatments control symptoms best in everyday care.
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
Hear when a new Ocular Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.